The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Johnson & Johnson introduces the TECNIS Odyssey IOL in India, enhancing vision for cataract patients with advanced technology.

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

Johnson & Johnson is expanding its presbyopia-correcting intraocular lenses (PC-IOL) portfolio in India with the new TECNIS Odyssey IOL.

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...